Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence

Abstract

Ruxolitinib is the only therapy with an approved indication for myelofibrosis (MF), a myeloproliferative neoplasm associated with progressive bone marrow fibrosis and extramedullary hematopoiesis. Although the pivotal phase 3 COMFORT studies included only patients with intermediate-2 or high-risk MF, the US indication includes all patients with intermediate- or high-risk disease. Data from recent nonrandomized studies confirm that the benefits of ruxolitinib established in the COMFORT studies in terms of spleen size reduction and symptom improvement also extend to patients with intermediate-1 risk MF, who tend to have less advanced disease than patients with higher-risk MF. Given the disease-modifying potential of ruxolitinib therapy, timely initiation of ruxolitinib therapy may not only improve patients’ current clinical status but also lead to better long-term outcomes. The decision of whether or when to initiate ruxolitinib treatment should be based on the expected benefit–risk ratio for each patient, specifically considering potential adverse effects.

Keywords:

• Intermediate-1 risk
• International Prognostic Scoring System
• myelofibrosis
• ruxolitinib
• splenomegaly

Acknowledgments

Medical writing support was provided by Roland Tacke, PhD, of Evidence Scientific Solutions, Philadelphia, Pennsylvania, USA, and funded by Incyte Corporation.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at http://dx.doi.org/10.1080/10428194.2016.1195501.